Cargando…

Experiencia de la citorreducción con peritonectomía y quimioterapia intraperitoneal hipertérmica en cáncer de ovario

BACKGROUND: Currently, epithelial ovarian cancer is diagnosed in advanced stages (EC IIIC) in 75-80% of cases worldwide. In this group of patients treatment with neoadjuvant chemotherapy is started, followed by interval cytoreduction of residual disease and even require peritonectomy with applicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Gómez, Héctor, Peña-Arriaga, Magaly Denise, Sánchez-Chimalpopoca, Fernando, Servín-Hernández, Carlos Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Mexicano del Seguro Social 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484554/
https://www.ncbi.nlm.nih.gov/pubmed/37535978
http://dx.doi.org/10.5281/zenodo.8200105
_version_ 1785102604651462656
author Martínez-Gómez, Héctor
Peña-Arriaga, Magaly Denise
Sánchez-Chimalpopoca, Fernando
Servín-Hernández, Carlos Alberto
author_facet Martínez-Gómez, Héctor
Peña-Arriaga, Magaly Denise
Sánchez-Chimalpopoca, Fernando
Servín-Hernández, Carlos Alberto
author_sort Martínez-Gómez, Héctor
collection PubMed
description BACKGROUND: Currently, epithelial ovarian cancer is diagnosed in advanced stages (EC IIIC) in 75-80% of cases worldwide. In this group of patients treatment with neoadjuvant chemotherapy is started, followed by interval cytoreduction of residual disease and even require peritonectomy with application of hyperthermic intraperitoneal chemotherapy (HIPEC). OBJECTIVE: To identify the overall survival and progression-free survival associated with peritonectomy, in patients with peritoneal carcinomatosis secondary to ovarian cancer treated in the oncology gynecology service from January 2009 to January 2019 at the UMAE Hospital de Oncología Centro Médico Nacional Siglo XXI. MATERIAL AND METHODS: Observational, descriptive, cross-sectional, retrospective study, information was obtained from the clinical file of patients treated with peritonectomy with the use of hyperthermic intraperitoneal chemotherapy in the gynecological oncology service from January 2009 to January 2019 at the UMAE Hospital de Oncología Centro Médico Nacional Siglo XXI. RESULTS: Information was obtained from a total of 36 patients (n=100%), 36.1% received intraperitoneal chemotherapy and 63.8% underwent cytoreduction without the application of intraoperative chemotherapy. The most frequently used drug was cisplatin followed by mitomycin. There was no statistical significance when comparing both groups, however there was a trend in favor of the use of intraoperative chemotherapy by obtaining a greater number of months in terms of overall survival. CONCLUSIONS: Peritonectomy with hyperthermic intraperitoneal chemotherapy is an option in selected patients with advanced stage ovarian cancer in primary and recurrent surgery, as well as in patients with platinum-resistant ovarian cancer.
format Online
Article
Text
id pubmed-10484554
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Instituto Mexicano del Seguro Social
record_format MEDLINE/PubMed
spelling pubmed-104845542023-09-08 Experiencia de la citorreducción con peritonectomía y quimioterapia intraperitoneal hipertérmica en cáncer de ovario Martínez-Gómez, Héctor Peña-Arriaga, Magaly Denise Sánchez-Chimalpopoca, Fernando Servín-Hernández, Carlos Alberto Rev Med Inst Mex Seguro Soc Aportación Original BACKGROUND: Currently, epithelial ovarian cancer is diagnosed in advanced stages (EC IIIC) in 75-80% of cases worldwide. In this group of patients treatment with neoadjuvant chemotherapy is started, followed by interval cytoreduction of residual disease and even require peritonectomy with application of hyperthermic intraperitoneal chemotherapy (HIPEC). OBJECTIVE: To identify the overall survival and progression-free survival associated with peritonectomy, in patients with peritoneal carcinomatosis secondary to ovarian cancer treated in the oncology gynecology service from January 2009 to January 2019 at the UMAE Hospital de Oncología Centro Médico Nacional Siglo XXI. MATERIAL AND METHODS: Observational, descriptive, cross-sectional, retrospective study, information was obtained from the clinical file of patients treated with peritonectomy with the use of hyperthermic intraperitoneal chemotherapy in the gynecological oncology service from January 2009 to January 2019 at the UMAE Hospital de Oncología Centro Médico Nacional Siglo XXI. RESULTS: Information was obtained from a total of 36 patients (n=100%), 36.1% received intraperitoneal chemotherapy and 63.8% underwent cytoreduction without the application of intraoperative chemotherapy. The most frequently used drug was cisplatin followed by mitomycin. There was no statistical significance when comparing both groups, however there was a trend in favor of the use of intraoperative chemotherapy by obtaining a greater number of months in terms of overall survival. CONCLUSIONS: Peritonectomy with hyperthermic intraperitoneal chemotherapy is an option in selected patients with advanced stage ovarian cancer in primary and recurrent surgery, as well as in patients with platinum-resistant ovarian cancer. Instituto Mexicano del Seguro Social 2023 /pmc/articles/PMC10484554/ /pubmed/37535978 http://dx.doi.org/10.5281/zenodo.8200105 Text en Licencia CC 4.0 (BY-NC-ND) © 2023 Revista Médica del Instituto Mexicano del Seguro Social. https://creativecommons.org/licenses/by-nc-nd/4.0/Esta obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
spellingShingle Aportación Original
Martínez-Gómez, Héctor
Peña-Arriaga, Magaly Denise
Sánchez-Chimalpopoca, Fernando
Servín-Hernández, Carlos Alberto
Experiencia de la citorreducción con peritonectomía y quimioterapia intraperitoneal hipertérmica en cáncer de ovario
title Experiencia de la citorreducción con peritonectomía y quimioterapia intraperitoneal hipertérmica en cáncer de ovario
title_full Experiencia de la citorreducción con peritonectomía y quimioterapia intraperitoneal hipertérmica en cáncer de ovario
title_fullStr Experiencia de la citorreducción con peritonectomía y quimioterapia intraperitoneal hipertérmica en cáncer de ovario
title_full_unstemmed Experiencia de la citorreducción con peritonectomía y quimioterapia intraperitoneal hipertérmica en cáncer de ovario
title_short Experiencia de la citorreducción con peritonectomía y quimioterapia intraperitoneal hipertérmica en cáncer de ovario
title_sort experiencia de la citorreducción con peritonectomía y quimioterapia intraperitoneal hipertérmica en cáncer de ovario
topic Aportación Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484554/
https://www.ncbi.nlm.nih.gov/pubmed/37535978
http://dx.doi.org/10.5281/zenodo.8200105
work_keys_str_mv AT martinezgomezhector experienciadelacitorreduccionconperitonectomiayquimioterapiaintraperitonealhipertermicaencancerdeovario
AT penaarriagamagalydenise experienciadelacitorreduccionconperitonectomiayquimioterapiaintraperitonealhipertermicaencancerdeovario
AT sanchezchimalpopocafernando experienciadelacitorreduccionconperitonectomiayquimioterapiaintraperitonealhipertermicaencancerdeovario
AT servinhernandezcarlosalberto experienciadelacitorreduccionconperitonectomiayquimioterapiaintraperitonealhipertermicaencancerdeovario